Joanne Hawana discusses recent actions taken by FDA with regard to regenerative medicine including clarifying what technologies fit within the rubric, the announcement of a wholesale review of polices, and recent enforcement activity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.